Entera Bio

Entera Bio

Yahoo Finance • 4 days ago

Entera Bio to Participate in the Canaccord Genuity 46th Annual Growth Conference

TEL AVIV, July 31, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced that the Company’s Chief Executive Officer, Miranda Toledano, will be p... Full story

Yahoo Finance • 8 days ago

Top Biotech Gainers: GOSS To File Seralutinib NDA In Sep, OMER Gains On AZN's Loss, FBRX Acquired

(RTTNews) - Today's top biotech gainers include Entera Bio, following an oversubscribed private placement financing; Gossamer, which is progressing toward a planned Seralutinib NDA submission in September; First Tracks, which has been firi... Full story

Yahoo Finance • 19 days ago

Top Biotech Gainers: CDNA Soars On Medicare Policy, ATAI Acquired, ABT Lifts Outlook, APLM On Watch

(RTTNews) - Today's top gainers in the biotech space include CareDx, which rallied after Medicare finalized its Local Coverage Determination process for molecular testing of solid organ allograft rejection; AtaiBeckley, after agreeing to b... Full story

Yahoo Finance • last month

Entera Bio Receives Positive FDA Feedback on 12-Month Registrational Phase 3 Study for EB613 - the First Oral Anabolic Tablet in Development for Postmenopausal Women with Osteoporosis

The planned Phase 3 trial in approximately 750 postmenopausal women with osteoporosis, with a primary endpoint of total hip bone mineral density (BMD) at Month 12, would support Entera’s plan to submit a New Drug Application (NDA) for EB61... Full story

Yahoo Finance • 2 months ago

Entera Reports Robust Preclinical Data for EB612 (Oral LA-PTH(1-34)) for Hypoparathyroidism and EB618 (Oral GLP-1/Glucagon) for Obesity at ENDO 2026

EB612, a first-in-class long-acting PTH(1-34) oral peptide  for hypoparathyroidism, produced robust bioavailability and sustained increases in calcium across three preclinical models; IND is expected in late 2026 EB618, a first-in-class d... Full story

Yahoo Finance • 2 months ago

ENDO 2026 Oral Presentation Highlights Comparative Clinical Data for Entera’s Breakthrough Single Tablet EB613 (First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis)

Entera Bio Ltd. The pharmacokinetic (PK) and pharmacodynamic (PD) profiles of single tablet EB613, multi-tablet EB613 and Forteo® reported for the first time as an oral presentation at ENDO 2026 Single tablet EB613 achieved a comparable... Full story

Yahoo Finance • 3 months ago

Entera Bio GAAP EPS of -$0.07 beats by $0.02

* Entera Bio press release [https://seekingalpha.com/pr/20508125-entera-announces-first-quarter-2026-financial-results-and-updates-across-its-oral-peptide] (ENTX [https://seekingalpha.com/symbol/ENTX]): Q1 GAAP EPS of -$0.07 beats by $0.... Full story

Yahoo Finance • 3 months ago

Entera Announces First Quarter 2026 Financial Results and Updates Across its Oral Peptide Programs

EB613, the first oral anabolic (bone building) peptide tablet for postmenopausal women with osteoporosis – Phase 3 protocol submitted with FDA feedback expected imminently; incremental data submitted to ENDO2026 and ASBMR EB612, the first... Full story

Yahoo Finance • 4 months ago

Entera Bio prices $10M direct investment, sees up to $24.5M in total proceeds

* Entera Bio (ENTX [https://seekingalpha.com/symbol/ENTX]) said [https://seekingalpha.com/pr/20460875-entera-bio-announces-pricing-of-10_0-million-direct-investment-by-bvf-partners-with-potential] on Thursday it had entered into a securi... Full story

Yahoo Finance • 4 months ago

Entera Bio Announces Full Year 2025 Financial Results and Provides Business Updates

EB613, the first oral anabolic (bone building) peptide tablet for postmenopausal women with osteoporosis – FDA Type A endpoint alignment in July 2025, Phase 3 protocol submitted to the FDA with comments expected in early Q2 2026 EB612, th... Full story

Yahoo Finance • 5 months ago

Entera Bio Submits Streamlined Phase 3 Protocol to Initiate Registrational Program for EB613 in Postmenopausal Women with Osteoporosis

Phase 3 study designed with total hip BMD primary endpoint assessed at 12 months, rather than at 24 months EB613 single tablet final commercial formulation (Next-Gen EB613) replaces multi-tablet EB613 as Phase 3 candidate, following succe... Full story

Yahoo Finance • 6 months ago

Opko Health (OPK) Expands Entera Partnership for Drug Co-Development

Opko Health Inc. (NASDAQ:OPK) is one of the best stocks under $3 to invest in. On February 4, Opko Health Inc. (NASDAQ:OPK) announced it expanded its partnership with Entera Bio Ltd., a company developing oral peptide and protein replaceme... Full story

Yahoo Finance • 9 months ago

Entera Bio to Participate in the 8th Annual Evercore ISI Healthcare Conference

JERUSALEM, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (Nasdaq: ENTX), (“Entera” or the “Company”) a leader in the development of oral peptide and protein replacement therapies, today announced that the Company’s Chief Executive Of... Full story

Yahoo Finance • 9 months ago

Entera Bio GAAP EPS of $0.07

* Entera Bio press release [https://seekingalpha.com/pr/20308640-entera-bio-announces-third-quarter-2025-financial-results-and-business-updates] (ENTX [https://seekingalpha.com/symbol/ENTX]): Q3 GAAP EPS of $0.07. * Research and develo... Full story

Yahoo Finance • 9 months ago

Entera Bio Announces Third Quarter 2025 Financial Results and Business Updates

FDA Agreement on BMD as Primary Endpoint for EB613 Registrational, Phase 3 Study EB613 Phase 2 Data Demonstrating Consistent Efficacy across Younger Post-Menopausal Women with Osteoporosis and its Impact on Trabecular and Cortical Bone In... Full story

Yahoo Finance • 10 months ago

Entera Bio to Present New Clinical Data from Phase 2 Trial of EB613 at the 2025 North American Menopause Society (NAMS) Annual Meeting

JERUSALEM, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptide and protein replacement therapies, today announced that it will present new clinical data from its Phase 2 trial of... Full story

Yahoo Finance • 12 months ago

Entera Bio GAAP EPS of -$0.06 beats by $0.10

* Entera Bio press release [https://seekingalpha.com/pr/20195250-entera-bio-announces-second-quarter-2025-financial-results-and-business-updates] (NASDAQ:ENTX [https://seekingalpha.com/symbol/ENTX]): Q2 GAAP EPS of -$0.06 beats by $0.10.... Full story

Yahoo Finance • 12 months ago

Entera Bio Announces Second Quarter 2025 Financial Results and Business Updates

FDA provides pivotal agreement on EB613 Phase 3 design, confirming Bone Mineral Density (BMD) as primary endpoint and clearing streamlined pathway for first oral anabolic osteoporosis treatment Significant regulatory and pipeline advanceme... Full story

Yahoo Finance • last year

OPKO Health Reports Second Quarter 2025 Business Highlights and Financial Results

OPKO Health, Inc. Conference call begins at 4:30 p.m. Eastern time today MIAMI, July 31, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and six months ended June 3... Full story

Yahoo Finance • last year

Entera Bio Receives FDA Agreement on BMD as Primary Endpoint for EB613 Registrational, Phase 3 Study in Post-Menopausal Women with Osteoporosis

JERUSALEM, July 28, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptides and protein replacement therapies, announced today that in a written response to a Type A meeting request, the U.S.... Full story